Moscow, Russia, January 2014. "TheraMAB" LLC. announces the beginning of multicenter Phase Ib/IIa clinical trial of multiple TAB08 i.v. administration. This is “first-in-class” anti-CD28 humanized mAb of IgG4 type for the treatment...
Moscow, Russia, November, 2011. "TheraMAB" announced an important step in TAB08 development: the first volunteer was enrolled in the phase I clinical trial, a humanized antibody for the treatment of autoimmune diseases and hemo-oncological disorders...
Moscow, Russia, March, 2012. "TheraMAB" has announced the closing of its 2nd venture investment tranche of RUB 157 million "TheraMAB" LLC., a Russian biotech company developing therapeutic antibody targeting serious medical diseases...
Moscow, Russia, September, 2009. "TheraMAB" has announced the closing of its 1st venture investment tranche of RUB 192 million "TheraMAB" LLC., a Russian biotech company developing therapeutic antibody targeting serious medical diseases...
August, 18, 2011, TheraMAB LLC. earned the resident status at the business and innovation center of “Skolkovo” Fund at the inauguration ceremony in Gorky Central Park of Culture and Leisure. The innovation project was highly appreciated by “Skolkovo”...